Literature DB >> 21852110

CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells.

Silke Reinartz1, Sophie Failer, Tina Schuell, Uwe Wagner.   

Abstract

The tumour-associated antigen CA125 (mucin 16, MUC16) is commonly expressed in ovarian cancer, and can also be detected in other tumour of epithelial origin, but its physiological role is largely unknown. The aim of the present study was to investigate the impact of MUC16 gene silencing on the growth properties of ovarian and breast cancer cells. We analysed cellular effects linked to oncogenesis, such as proliferation, cell cycle and apoptosis, after transient and stable transfection with MUC16 short hairpin RNA (shRNA) in diverse epithelial cancer cell lines with different MUC16 expression. Furthermore, alterations in cell adhesion, migration and invasion were evaluated in stable MUC16 knockdown clones. The growth of all tested MUC16(+) tumour cells was significantly suppressed by induction of caspase-dependent apoptosis after transient transfection with MUC16 shRNA, irrespective of the initial MUC16 expression level and cancer origin. Growth inhibition could be confirmed in stable MUC16 knockdown clones, albeit caspase-dependent death pathways seemed no longer be activated. In MUC16(low+) ovarian cancer cells, stable MUC16 gene silencing resulted in a substantial blockade of colony formation, cell adhesion, migration and invasiveness associated with reduced activation of metalloproteinases-2 (MMP-2). By contrast, the tested MUC16(high+) cell lines displayed a non-motile and non-invasive phenotype which was not affected by MUC16 knockdown, probably due to the expression of different MUC16 isoforms with divergent functions in individual cell lines. Our results provide evidence for a central role of MUC16 in cancer cell survival pathways. Additionally, MUC16 might also be involved in adhesion, migration and invasion depending on the type of cancer cell.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21852110     DOI: 10.1016/j.ejca.2011.07.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  27 in total

1.  MUC16 suppresses human and murine innate immune responses.

Authors:  Mildred Felder; Arvinder Kapur; Alexander L Rakhmilevich; Xiaoyi Qu; Paul M Sondel; Stephen D Gillies; Joseph Connor; Manish S Patankar
Journal:  Gynecol Oncol       Date:  2019-01-06       Impact factor: 5.482

2.  The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia.

Authors:  Chanel Tyler; Arvinder Kapur; Mildred Felder; Jennifer A Belisle; Christine Trautman; Jennifer A A Gubbels; Joseph P Connor; Manish S Patankar
Journal:  Am J Reprod Immunol       Date:  2012-03-01       Impact factor: 3.886

3.  MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

Authors:  Panagiota Giannakouros; Marina Comamala; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 4.  Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwendlyn Kollmorgen; Rüdiger Rueger
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

5.  ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.

Authors:  Sai Kiran Sharma; Kyeara N Mack; Alessandra Piersigilli; Jacob Pourat; Kimberly J Edwards; Outi Keinänen; Maria S Jiao; Huiyong Zhao; Brandy White; Cory L Brooks; Elisa de Stanchina; Madi R Madiyalakan; Michael A Hollingsworth; Prakash Radhakrishnan; Jason S Lewis; Brian M Zeglis
Journal:  Clin Cancer Res       Date:  2022-03-01       Impact factor: 12.531

6.  Immunobiology of human mucin 1 in a preclinical ovarian tumor model.

Authors:  R A Budiu; E Elishaev; J Brozick; M Lee; R P Edwards; P Kalinski; A M Vlad
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

Review 7.  MUC16 as a novel target for cancer therapy.

Authors:  Abhijit Aithal; Sanchita Rauth; Prakash Kshirsagar; Ashu Shah; Imayavaramban Lakshmanan; Wade M Junker; Maneesh Jain; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Expert Opin Ther Targets       Date:  2018-07-26       Impact factor: 6.902

8.  Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.

Authors:  Wei Li; Hong Wu; Xuewen Xu; Yange Zhang
Journal:  Aging (Albany NY)       Date:  2021-04-18       Impact factor: 5.682

9.  Genomic alterations in breast cancer patients in betel quid and non betel quid chewers.

Authors:  Mishi Kaushal; Ashwani K Mishra; Jagannath Sharma; Eric Zomawia; Amal Kataki; Sujala Kapur; Sunita Saxena
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

Review 10.  Mucin in cancer: a stealth cloak for cancer cells.

Authors:  Dong-Han Wi; Jong-Ho Cha; Youn-Sang Jung
Journal:  BMB Rep       Date:  2021-07       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.